Cargando…

Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers

OBJECTIVES: To develop and validate a radiomics model for evaluating treatment response to immune-checkpoint inhibitor plus chemotherapy (ICI + CT) in patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS: A total of 64 patients with advance ESCC receiving first-line ICI + CT at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Ying, Yao, Wang, Xu, Bing-Chen, Lei, Yi-Yan, Guo, Qi-Kun, Liu, Li-Zhi, Li, Hao-Jiang, Xu, Min, Yan, Jing, Chang, Dan-Dan, Feng, Shi-Ting, Zhu, Zhi-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557514/ https://www.ncbi.nlm.nih.gov/pubmed/34717582 http://dx.doi.org/10.1186/s12885-021-08899-x

Ejemplares similares

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
por: Zhao, Junfeng, et al.
Publicado: (2023)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy
por: Li, Yue, et al.
Publicado: (2021)

A Radiomics Nomogram for Non-Invasive Prediction of Progression-Free Survival in Esophageal Squamous Cell Carcinoma
por: Yan, Ting, et al.
Publicado: (2022)

Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
por: Liu, Min, et al.
Publicado: (2020)

Predicting response to CCRT for esophageal squamous carcinoma by a radiomics-clinical SHAP model
por: Cheng, Xu, et al.
Publicado: (2023)

CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy
por: Yan, Shuo, et al.
Publicado: (2023)

A CT-Based Radiomics Nomogram Model for Differentiating Primary Malignant Melanoma of the Esophagus from Esophageal Squamous Cell Carcinoma
por: Shi, Yan-Jie, et al.
Publicado: (2023)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma
por: Xu, Yi-Wei, et al.
Publicado: (2014)

The prognostic effect of perineural invasion in esophageal squamous cell carcinoma
por: Chen, Jie-Wei, et al.
Publicado: (2014)

DCE-MRI radiomics nomogram can predict response to neoadjuvant chemotherapy in esophageal cancer
por: Qu, Jinrong, et al.
Publicado: (2022)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma
por: Li, Yang, et al.
Publicado: (2021)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer
por: Wu, Sheng-Xi, et al.
Publicado: (2017)

Corrigendum: Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma
por: Li, Yang, et al.
Publicado: (2021)

Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System
por: Ji, Zhi, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Prognostic Significance of the pN Classification Supplemented by Vascular Invasion for Esophageal Squamous Cell Carcinoma
por: Zhu, Chong-Mei, et al.
Publicado: (2014)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
por: Zhou, Chongchong, et al.
Publicado: (2023)

Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)
por: Zhang, Zhenyang, et al.
Publicado: (2021)

Surgery, adjuvant immunotherapy plus chemotherapy and radiotherapy for primary malignant melanoma of the parotid gland (PGMM): A case report
por: Zhao, Qiang, et al.
Publicado: (2023)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

Role of ferroptosis in esophageal cancer and corresponding immunotherapy
por: Fan, Xin, et al.
Publicado: (2023)

Elevated serum eotaxin and IP‐10 levels as potential biomarkers for the detection of esophageal squamous cell carcinoma
por: Chang, Chen, et al.
Publicado: (2021)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Lin, Ying-Tao, et al.
Publicado: (2023)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Serum Metabolomics for Biomarker Screening of Esophageal Squamous Cell Carcinoma and Esophageal Squamous Dysplasia Using Gas Chromatography-Mass Spectrometry
por: Zhang, Su, et al.
Publicado: (2020)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1
por: Chang, Zhi-wei, et al.
Publicado: (2018)

Perioperative treatment and biomarker analysis of LP002, an anti‐PD‐L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer
por: Tang, Jia‐lin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj9m91brfgbmj2km05norl0mrj